Next Article in Journal
Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib
Next Article in Special Issue
Oleacein Intestinal Permeation and Metabolism in Rats Using an In Situ Perfusion Technique
Previous Article in Journal
Combined Self-Nanoemulsifying and Solid Dispersion Systems Showed Enhanced Cinnarizine Release in Hypochlorhydria/Achlorhydria Dissolution Model
Previous Article in Special Issue
Physico-Chemical and In Vitro Characterization of Chitosan-Based Microspheres Intended for Nasal Administration
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 13
Issue 5
10.3390/pharmaceutics13050628
Review Report
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

Printed Edition

A printed edition of this Special Issue is available at MDPI Books....
share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Enhanced Bioavailability and Efficacy of Silymarin Solid Dispersion in Rats with Acetaminophen-Induced Hepatotoxicity

Pharmaceutics 2021, 13(5), 628; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13050628
by Im-Sook Song 1,*, So-Jeong Nam 1, Ji-Hyeon Jeon 1, Soo-Jin Park 2 and Min-Koo Choi 3,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Pharmaceutics 2021, 13(5), 628; https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13050628
Submission received: 17 March 2021 / Revised: 20 April 2021 / Accepted: 26 April 2021 / Published: 28 April 2021
(This article belongs to the Special Issue Drug Absorption Studies: In Situ, In Vitro and In Silico Models)

Round 1

Reviewer 1 Report

The authors investigated bioavailability and efficacy of silymarin in rats with acetaminophen-induced hepatotoxicity by SD. The paper is in line with the journal scope. The following items are suggested for correction.

Line 53-55, rewrite the sentence

L 57-60 these information can be paced in the second paragrah. It is not necesarry to be an individual paragrah

The introdution need to be rewritten. Information on solubility enhancements of silymarin should be state in detail. What is the novlty of this study, which could not be seen from the introdution.

L80-86, please give the CAS nummber

L91-94 the X-ray diffraction section belongs to the characterization, not the preparation of silymarin-DS.

L103 What is silymarin SD? Is it the same as “silymarin-SD”?

L109  Does “silymarin-SD” refer to dired silymarin-SD? It is confused to name the solid dispersion. Because in section 2.2, “Silymarin-SD“ was in a solid state (frozen). “Silymarin-SD“was dired to produce dried “silymarin-SD”.

What is the load efficiency of silymarin in the SD?

Section 2.4 why the number of the control rats and APAP rats were 4? The number is too small to observe and obtain precise results.

Is there any relationship between the X-ray diffraction reults and the solubility of silymarin-SD?

Table 1 The significant digits of the data should be the same.

 

Author Response

please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

The manuscript is well written. however, following suggestion can be considered.

  1. Please describe the detailed formulation development
  2. No results are provided for other API:Polymer ratio
  3. What is the glass transition temperature of the dispersion?
  4. Please include DSC data as it can give more information for miscibility of the API and polymer and stability of the dispersion.
  5. Is any supporting studies like FTIR is done to study the drug polymer interactions? If yes, it will be good to include.

Author Response

Please see the attached file

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

The Authors have revised the manuscript thoroughly. 

Back to TopTop